Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in metastatic ER-positive breast cancer
NCT02414776Phase 1Terminated
- Sponsor
- Western Regional Medical Center
- Start
- Jul 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydroxychloroquine in estrogen receptor-positive breast cancer (ER+), sponsored by Western Regional Medical Center. Primary endpoint: Number of Participants with Adverse Events at 18 months. Started Jul 2014; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT02414776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02414776.